Drug Profile

GRC 15300

Alternative Names: GRC 17173; GRC15300; SAR 292833

Latest Information Update: 05 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Glenmark Pharmaceuticals Ltd
Developer Glenmark Pharmaceuticals Ltd; Sanofi
Class Analgesics
Mechanism of Action TRPV3 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Musculoskeletal pain; Neuropathic pain; Skin disorders; Urinary incontinence

Most Recent Events

31 May 2013 Sanofi completes the phase II Alchemilla trial in Neuropathic pain in USA, Czech Republic, Hungary, Poland, Russia, Slovakia & Ukraine (NCT01463397)
05 Mar 2012 Phase-II clinical trials in Neuropathic pain in Czech Republic (PO)
05 Mar 2012 Phase-II clinical trials in Neuropathic pain in Hungary (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com